Madhav Menon is a Nephrology physician affiliated with Yale New Haven Hospital. OpenAlex indexes 173 publications with 3,246 citations (h-index 30); ClinicalTrials.gov lists 2 registered studies matched to this name.
Overview
Scholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex, matched via ORCID.
Total citations across indexed works.
Hirsch index, productivity × impact (OpenAlex).
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
Yale Physicians Building
800 Howard Ave, Ste 4th Floor
New Haven, CT 06520
Telephone
203-737-1204Provider last certified this registry record 5 Jan 2021.
Clinical trials
- AMPK-activation by Metformin in FSGS: AMP-FSGS
Sponsor: Yale University
- Ffr-gUidance for compLete Non-cuLprit REVASCularization
Sponsor: Felix Bohm
Registered studies on ClinicalTrials.gov where the overall official or a site investigator name-matches this physician, confirmed against known institution/geography. Latest few shown; the full list is part of the full profile.
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Metabolism & gastrointestinal
36.3%H2 blocker22.1%Famotidine100%Part D<11 patientsCorticosteroid14.2%Prednisone100%Part D<11 patientsHormonal (systemic)
21.2%Calcium-sensing Receptor Agonist21.2%Cinacalcet Hcl100%Part D<11 patientsAnti-infectives
19.5%Short-acting sulfonamides19.5%Sulfamethoxazole-Trimethoprim100%Part D<11 patients
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
NIH funding
3 NIH research awards on record, funded 2021–2026 per NIH RePORTER. The latest:
- Cell-type specific inhibition of Shroom3-Rock interaction to mitigate progressive tubulointerstitial fibrosis
Yale University
FY2026$828,500R01DK122164 - Role of AMP-kinase pathway in the regulation of Minimal change disease-to-FSGS transition
Yale University
FY2026$495,830R01DK132274 - Role of AMP-kinase pathway in the regulation of Minimal change disease-to-FSGS transition
Yale University
FY2025$497,321R01DK132274
Awards in the NIH RePORTER records where a principal investigator name matches this physician at an organization in their practice state. Latest award years shown; each row links to the project record on RePORTER.
Publications
Matched to this physician's OpenAlex author record; most-cited works shown first.
- Profilin1 is required for prevention of mitotic catastrophe in murine and human glomerular diseases
Journal of Clinical Investigation
2023
Similar KOLs
Other experts from the same institution or the same specialty.
Gerard Sanacora, MD, PhD
Yale New Haven Hospital
John Elefteriades, MD
Yale New Haven Hospital
Jeptha Curtis, MD
Yale New Haven Hospital
Erica Spatz, MD
Yale New Haven Hospital
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments — shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”